Toss, A. Isca, C. Venturelli, M. Nasso, C. Ficarra, G. Bellelli, V. Armocida, C. Barbieri, E. Cortesi, L. Moscetti, L.
...
Published in
ESMO Open
Introduction The present analysis aims to evaluate the consequences of a 2-month interruption of mammographic screening on breast cancer (BC) stage at diagnosis and upfront treatments in a region of Northern Italy highly affected by the severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) virus. Methods This retrospective single-ins...
Danesi, R. Fogli, S. Indraccolo, S. Del Re, M. Dei Tos, A.P. Leoncini, L. Antonuzzo, L. Bonanno, L. Guarneri, V. Pierini, A.
...
Published in
ESMO Open
• The identification of oncogenic drivers offers the opportunity to develop target-specific drugs. • The inhibition of crucial pathways realizes the principle of druggable target to exploit cancer vulnerability. • The approval of new anticancer agents based on target-based concept represents a paradigm shift in cancer therapy. • However, only few d...
Brahmi, M. Lesluyes, T. Dufresne, A. Toulmonde, M. Italiano, A. Mir, O. Le Cesne, A. Valentin, T. Chevreau, C. Bonvalot, S.
...
Published in
ESMO Open
• The expression of PDGF ligands and receptors substantially varies across sarcoma histological subtypes. • PDGFA and D expression levels independently and inversely correlate with the risk of metastatic relapse. • The differential expression of ligands might be used as biomarker of efficacy for PDGFRα antibodies in STS.
Lee, R.J. Wysocki, O. Bhogal, T. Shotton, R. Tivey, A. Angelakas, A. Aung, T. Banfill, K. Baxter, M. Boyce, H.
...
Published in
ESMO Open
Heudel, P. Chabaud, S. Perol, D. Flechon, A. Fayette, J. Combemale, P. Tredan, O. Desseigne, F. de la Fouchardiere, C. Boyle, H.
...
Published in
ESMO Open
• From 2013 to 2018, 3.9% of the 46 829 patients diagnosed with a first cancer presented with an SPC. • Treatment of the first cancer with ICIs was associated with a major reduction of SPC. • CC given for an FPC was also associated with a lower magnitude of reduction of SPC. • There were no SPC in cancer patients treated with ICIs in the localized ...
Gomes, F. Lorigan, P. Woolley, S. Foden, P. Burns, K. Yorke, J. Blackhall, F.
Published in
ESMO Open
• The ELDERS is the first prospective study designed to address the safety of immunotherapy in older cancer patients. • Older cancer patients had no increased risk of high-grade toxicity with immunotherapy. • Management of immune toxicity in older patients is often more challenging, particularly for those more vulnerable/frail. • Geriatric assessme...
Viñal, D. Martínez, D. Higuera, O. de Castro, J.
Published in
ESMO Open
• Lung cancer in adolescents and young adults (AYA) has specific features that may unveil a unique genomic background. • AYA harbor a higher percent of oncogenic genomic alterations, gene fusions, and a different profile of gene alterations. • Comprehensive genomic profiling is strongly recommended to offer the best treatment available. • In driver...
Drabbe, C. Van der Graaf, W.T.A. De Rooij, B.H. Grünhagen, D.J. Soomers, V.L.M.N. Van de Sande, M.A.J. Been, L.B. Keymeulen, K.B.M.I. van der Geest, I.C.M. Van Houdt, W.J.
...
Published in
ESMO Open
• In the very heterogeneous sarcoma survivor population, there is also a wide variety in HRQoL scores. • Sarcoma and its treatment have a greater impact on the HRQoL of younger survivors than on the HRQoL of older survivors. • Younger survivors reported worse scores on emotional and cognitive functioning compared with older survivors. • Receiving c...
Cai, Z. Zhang, J. He, Y. Xia, L. Dong, X. Chen, G. Zhou, Y. Hu, X. Zhong, S. Wang, Y.
...
Published in
ESMO Open
• A novel liquid biopsy approach was developed for HCC diagnosis, prognosis, and surveillance. • Novel HCC score defined here showed excellent capacity in distinguishing HCC patients from liver cirrhosis patients. • HCC score could predict the early recurrence risk for HCC patients after receiving surgical operation. • HCC score could sensitively m...
Fucà, G. Spagnoletti, A. Ambrosini, M. de Braud, F. Di Nicola, M.
Published in
ESMO Open
• Immune cell engagers (ICEs) are molecules able to redirect immune effector cells against cancer cells. • ICEs can be used for the redirection of T cells, natural killer (NK) cells and cytotoxic/phagocytic cells. • ICEs have the potential for enabling a feasible and effective redirection of effector cells in patients with solid tumors. • ICEs desi...
